Amidst a period of significant pressure on its share price, a notable insider transaction at Siemens Healthineers has captured market attention. The purchase by supervisory board member Dorothea Simon occurred precisely as the stock touched a fresh 52-week low last Friday. This move highlights a potential divergence between the company’s internal confidence and its current market valuation, set against a backdrop of strategic change and operational headwinds.
Operational Headwinds and Strategic Shifts
The stock concluded the recent trading week at €36.37, marking an 18% decline since the start of the year. This downward trajectory is attributed to several concurrent challenges. A primary concern is the underperformance of the diagnostics division in China, where segment revenue contracted by 3% last quarter. This weakness has led management to project growth for the current second quarter below its medium-term target range of 5 to 6 percent.
Simultaneously, the company is preparing for a major corporate restructuring. Its parent company, Siemens AG, intends to distribute approximately 30% of its Siemens Healthineers stake directly to Siemens shareholders, thereby relinquishing its majority control. Despite these pressures, the executive board has reaffirmed its full-year guidance, forecasting adjusted earnings per share between €2.20 and €2.40.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Core Strength and External Risks
Beyond the challenges in Asia, Siemens Healthineers’ core operations demonstrate resilience. The key imaging and advanced therapy segments continue to serve as reliable growth engines, contributing to a 3.8% increase in total group revenue recently. The adjusted operating margin also showed marked improvement, rising to 15%.
However, external risks loom on the horizon. US trade policy presents a substantial potential headwind. With around 40% of the group’s revenue generated in the United States and a significant portion of costs denominated in euros, management estimates potential tariff impacts of up to €500 million for the current fiscal year. A strengthening euro would further exacerbate this currency effect.
Forthcoming Catalysts
The calendar holds specific events that are likely to influence the investment narrative. In early April, management is scheduled to present detailed plans regarding the structure and timeline of the planned spin-off. This will be followed by the release of second-quarter results on May 7, 2026, which will serve as the next key test of the company’s fundamental performance amidst the ongoing operational adjustments.
Ad
Siemens Healthineers Stock: Buy or Sell?! New Siemens Healthineers Analysis from March 23 delivers the answer:
The latest Siemens Healthineers figures speak for themselves: Urgent action needed for Siemens Healthineers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 23.
Siemens Healthineers: Buy or sell? Read more here...
